Fagron Sterile Services US

Fagron Sterile Services US is an FDA-registered, DEA-licensed 503B outsourcing facility headquartered in Wichita, KS, operating as part of the globally integrated Fagron group. Trusted by thousands of clinicians and serving millions of patients each year, the organization occupies a significant role in the sterile compounding landscape by providing hospitals, health systems, and clinical practices with reliable, high-quality sterile medications — including peptide-containing formulations intended for professional clinical use. As a verified listing on The Peptide Alliance directory, Fagron Sterile Services US represents the type of regulated, institutional-scale compounding operation that industry professionals and procurement teams seek when sourcing specialty sterile compounds.

As a full-service 503B outsourcing compounding pharmacy, Fagron Sterile Services US maintains a broad and diverse portfolio spanning multiple therapeutic categories. Their product catalog covers critical care, labor and delivery, ophthalmic preparations, pain management, and specialty presentations, among other areas. For clinicians and procurement professionals researching compounding pharmacies, this depth of catalog is a defining advantage — offering a consolidated source for sterile medications across the continuum of care. The facility's operational model is designed to support supply chain resiliency, reducing dependency on single-source suppliers and helping healthcare institutions maintain consistent medication availability for patient populations.

Within the peptide industry, Fagron Sterile Services US occupies a position of institutional credibility, backed by the global infrastructure of the Fagron group. Their national reach means that healthcare facilities across the United States can access their portfolio of sterile compounded products, regardless of geographic location. This national distribution capability places them among the compounding pharmacies best positioned to serve large health systems, ambulatory surgery centers, and specialty clinics that require consistent, scalable supply of sterile formulations. The scale and vertical integration of their operations allow them to proactively address demand fluctuations that often affect smaller or regionally limited compounding pharmacies.

When evaluating compounding pharmacies for procurement or clinical sourcing decisions, healthcare professionals prioritize regulatory standing, quality systems, and supply chain transparency. Fagron Sterile Services US operates under the 503B outsourcing facility framework, a designation established under federal law that imposes heightened oversight requirements compared to traditional compounding models. Facilities operating under this framework are subject to FDA registration, Current Good Manufacturing Practice (CGMP) standards, and regular inspections — considerations that are fundamental to any quality-focused sourcing evaluation. Professionals reviewing compounding pharmacy options are encouraged to verify regulatory status, review available quality documentation, and confirm that a facility's production capabilities align with their institution's specific clinical and formulary requirements.

Industry professionals, clinical procurement teams, and formulary decision-makers interested in learning more about available sterile compounded products are encouraged to connect directly with Fagron Sterile Services US through a consultation request or by downloading their product catalog. Whether you represent a hospital system, specialty clinic, or healthcare network evaluating compounding pharmacies for your supply chain strategy, Fagron Sterile Services US offers the regulatory pedigree, product breadth, and national reach to merit serious consideration. Visit their listing on The Peptide Alliance directory to access contact information and begin the conversation.